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Epithelial contribution to the profibrotic stiff 
microenvironment and myofibroblast population 
in lung fibrosis
ABSTRACT The contribution of epithelial-to-mesenchymal transition (EMT) to the profibrotic 
stiff microenvironment and myofibroblast accumulation in pulmonary fibrosis remains unclear. 
We examined EMT-competent lung epithelial cells and lung fibroblasts from control (fibrosis-
free) donors or patients with idiopathic pulmonary fibrosis (IPF), which is a very aggressive 
fibrotic disorder. Cells were cultured on profibrotic conditions including stiff substrata and 
TGF-β1, and analyzed in terms of morphology, stiffness, and expression of EMT/myofibroblast 
markers and fibrillar collagens. All fibroblasts acquired a robust myofibroblast phenotype on 
TGF-β1 stimulation. Yet IPF myofibroblasts exhibited higher stiffness and expression of fibril-
lar collagens than control fibroblasts, concomitantly with enhanced FAKY397 activity. FAK inhi-
bition was sufficient to decrease fibroblast stiffness and collagen expression, supporting that 
FAKY397 hyperactivation may underlie the aberrant mechanobiology of IPF fibroblasts. In con-
trast, cells undergoing EMT failed to reach the values exhibited by IPF myofibroblasts in all 
parameters examined. Likewise, EMT could be distinguished from nonactivated control fibro-
blasts, suggesting that EMT does not elicit myofibroblast precursors either. Our data suggest 
that EMT does not contribute directly to the myofibroblast population, and may contribute 
to the stiff fibrotic microenvironment through their own stiffness but not their collagen ex-
pression. Our results also support that targeting FAKY397 may rescue normal mechanobiology 
in IPF.
INTRODUCTION
Physiologic tissue stiffness supports tissue-specific functions and is 
maintained in normal homeostatic conditions. In contrast, normal 
tissue stiffness becomes chronically increased in a variety of preva-
lent diseases, including fibrosis, sclerosis, and cancer, where it is in-
creasingly pointed to as a major driving force of disease progression 
(Ingber, 2003; Butcher et al., 2009; Ho et al., 2014). In the context of 
pulmonary physiopathology, it is well known that lungs are soft and 
elastic organs, which enables the dramatic cyclic volume changes 
required for breathing. In contrast, normal pulmonary stiffness can 
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disorders, there is increasing interest in defining their cellular source. 
It remains widely accepted that lung myofibroblasts arise from the 
proliferation and migration of resident fibroblasts. In addition, alve-
olar epithelial cells undergoing epithelial-to-mesenchymal transition 
(EMT) have been pointed to as potential contributors to the myofi-
broblast population (Willis et al., 2006; Scotton and Chambers, 
2007; Hinz, 2012). During EMT, epithelial cells undergo a dramatic 
phenotypic change that includes loosening cell–cell adhesions, 
down-regulating epithelial markers, up-regulating mesenchymal 
markers and pro-EMT transcription factors, and acquiring an elon-
gated fibroblast-like morphology (Willis et al., 2006; Scotton and 
Chambers, 2007; Moreno-Bueno et al., 2009). In support of the EMT 
source of myofibroblasts, studies in vitro have revealed that EMT 
may be induced by TGF-β1 (Willis et al., 2006; Hinz, 2012; O’Connor 
and Gomez, 2014). Moreover, studies using in vivo models of pul-
monary fibrosis support that a significant fraction of fibroblasts in fi-
brotic lesions may be epithelial derived (Kim et al., 2006; Wu et al., 
2007; Kim et al., 2009; Degryse et al., 2010). Likewise, cells coex-
pressing epithelial and mesenchymal markers have been reported 
in IPF biopsies (Willis et al., 2005; Kim et al., 2006; Yamaguchi et al., 
2017). However, recent lineage tracing experiments have failed to 
unambiguously provide evidence of EMT in in vivo models of lung 
fibrosis (Rock et al., 2011; Ho et al., 2014), and technical concerns 
on previous EMT analyses of IPF biopsies have been raised (Rock 
et al., 2011). Similar controversial data have been reported in liver 
and kidney fibrosis (Humphreys et al., 2010; Bartis et al., 2014; 
Giannandrea and Parks, 2014; Ho et al., 2014). On the other hand, 
it should be mentioned that previous EMT studies have focused 
on the expression of epithelial and mesenchymal markers, whereas 
functional mechanical measurements have been largely absent. 
Accordingly, it remains unclear what the contribution of EMT is to 
the profibrotic stiff microenvironment and overall myofibroblast 
accumulation in IPF.
To shed light on these questions, we gathered a panel of EMT-
competent lung epithelial cells and primary lung fibroblasts derived 
from either fibrosis-free donors (used as control cell models for resi-
dent fibroblasts) or IPF patients. To mimic a profibrotic microenvi-
ronment, we cultured cells on stiff culture substrata in the presence 
of exogenous TGF-β1 at concentrations capable of inducing both 
EMT and fibroblast activation. The phenotypic effects of the profi-
brotic microenvironment were analyzed in terms of morphology and 
expression of both EMT and myofibroblast markers. To assess the 
potential impact of pro-fibrotic stimuli on tissue mechanics, we ana-
lyzed cellular stiffness through nanoindentation measurements by 
atomic force microscopy (AFM) as well as the expression of fibrillar 
collagens.
RESULTS
TGF-β1 induces EMT in selected lung epithelial cell lines but 
fails to match the vimentin expression levels and 
morphological features of IPF-derived fibroblasts
Unlike fibroblasts, isolating and maintaining human lung epithelial 
cells remains rather challenging and poorly efficient (Shannon et al., 
1987; Yu et al., 2007). To overcome these limitations, we selected a 
panel of lung epithelial cell lines previously reported to express lev-
els of epithelial and mesenchymal markers indicative of either a high 
(H441, PC9) or a moderate/low (A549, H1975) epithelial phenotype 
in basal conditions, which has been associated with poor or strong 
EMT competence, respectively (Thomson et al., 2005; Yauch et al., 
2005; Zhang et al., 2011; Jolly et al., 2016). Although these four cell 
lines were originally derived from lung adenocarcinomas, they were 
selected because they are accepted models of either poor or strong 
be increased up to 30-fold in pulmonary fibrotic disorders concomi-
tantly with a loss of normal pulmonary function and architecture (Liu 
et al., 2010; Hinz, 2012). Of note, such tissue stiffening remains cur-
rently irreversible in idiophatic pulmonary fibrosis (IPF), which is a 
very aggressive disease characterized by the progressive and 
chronic replacement of normal pulmonary tissue by a stiff dysfunc-
tional scar in the absence of any known cause (King et al., 2011; 
Hinz, 2012). Intriguingly, unlike other pulmonary fibrotic disorders, 
IPF remains frequently lethal due to suboptimal therapeutic options, 
with a median survival of only ∼2–5 yr from time of diagnosis 
(Blackwell et al., 2014). Moreover, it is worth noting that IPF is a rare 
disease that affects ∼5 million patients worldwide, yet it has a preva-
lence of ∼1/5000 people that continues to rise (King et al., 2011). 
Accordingly, there is an urgent need in understanding the critical 
mechanobiological alterations that drive this devastating disease.
IPF progression is associated with the appearance of areas of 
active fibrosis referred to as fibroblast foci, which are rich in acti-
vated fibroblasts/myofibroblasts in the background of abundant fi-
brillar collagens (Willis et al., 2006; Scotton and Chambers, 2007; 
King et al., 2011). Myofibroblasts have been identified as major driv-
ers of the progression of IPF and other fibrotic disorders (Hinz, 2012; 
Ho et al., 2014). Likewise, myofibroblasts have been pointed to as 
major effector cells of tissue stiffening, since they combine the extra-
cellular matrix (ECM)-synthesizing features of fibroblasts with the 
cytoskeletal characteristics of contractile smooth muscle cells. In-
deed, the most common myofibroblast markers are the abundant 
extracellular deposition of fibrillar collagens and the intracellular 
overexpression of alpha-smooth muscle actin (α-SMA) (King et al., 
2011; Hinz et al., 2012). Although the processes underlying the ab-
errant accumulation of myofibroblasts in IPF remain poorly under-
stood, it has been reported that transforming growth factor beta 1 
(TGF-β1), which is the most potent fibroblast activator cytokine char-
acterized to date, is frequently upregulated in fibrotic lung diseases 
(Willis et al., 2006; Scotton and Chambers, 2007; King et al., 2011). 
Moreover, studies using hydrogel-based culture substrata with tun-
able elasticity have revealed that TGF-β1 can induce α-SMA expres-
sion in stiff but not in soft substrata (Arora et al., 1999; Balestrini 
et al., 2012; Hinz, 2012), thereby underscoring the prominent role of 
tissue stiffening in organ fibrosis.
In addition to α-SMA up-regulation, there is growing evidence 
that matrix stiffening alone can trigger the expression of collagens 
and other profibrotic factors independently of TGF-β1 in fibroblasts 
(Ebihara et al., 2000; Liu et al., 2010; Thannickal et al., 2014). More-
over, we recently showed that fibrosis-like extracellular rigidities 
alone can enhance the growth and survival of lung fibroblasts 
through β1 integrin and pFAKY397 signaling (Puig et al., 2015). Con-
versely, it was reported that extracellular stiffening strongly sup-
pressed fibroblast expression of cyclooxygenase-2 (COX-2) and 
synthesis of prostaglandin E2 (PGE2), which is an autocrine inhibitor 
of fibrogenesis (Liu et al., 2010). More recently it was described that 
gradients of matrix stiffness reminiscent of those occuring in fibrotic 
tissues can attract fibroblasts through durotaxis (Liu et al., 2010; 
Lagares et al., 2016). Collectively, these previous in vitro studies sup-
port that tissue stiffening per se provides a strong profibrotic micro-
environment. In agreement with this interpretation, a panel of basic, 
translational, and clinical IPF researchers gathered in 2014 by the 
National Heart, Lung and Blood Institute in the United States high-
lighted the need to “elucidate the mechanisms of matrix stiffening 
and cell responses to increased stiffness” as an important future di-
rection in IPF research (Blackwell et al., 2014).
Given the prominent role of fibrogenic myofibroblasts in tissue 
stiffening and overall disease progression in IPF and other fibrotic 
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lial cell lines and primary fibroblasts were 
cultured on tissue culture plastic for 24 h in 
culture medium containing 10% fetal bovine 
serum (FBS), thereby facilitating cell attach-
ment to a rigid substrata (Paszek et al., 
2005). Next, cell cultures were washed, 
maintained in serum-free medium for 24 h 
to growth arrest and synchronize them, and, 
finally, stimulated for 3 d with serum-free 
medium (used as negative control) or 5 ng/
ml TGF-β1, which is a master regulator of 
fibrosis in the lung and other organs (Willis 
et al., 2006; Scotton and Chambers, 2007). 
The latter conditions have been extensively 
reported to be sufficient to induce both fi-
broblast activation as well as EMT in A549 
and other epithelial cell lines (Zhang et al., 
2011; Gabasa et al., 2013; Vizoso et al., 
2015; Yamaguchi et al., 2017).
As expected, immunofluorescence anal-
ysis revealed that TGF-β1 stimulation in-
duced EMT selectively in some of the epi-
thelial cell lines (Figure 1A and Supplemental 
Figure S1). Specifically, TGF-β1 increased 
the average expression of the mesenchymal 
marker vimentin by ∼50–100% in A549 and 
H1975 epithelial cells, whereas vimentin re-
mained virtually unaltered in H441 and PC9 
cell lines (Figure 1B). Likewise, vimentin lev-
els did not exhibit a significant fold increase 
in primary fibroblasts derived from differ-
ent randomly selected control donors or IPF 
patients on TGF-β1 treatment (Figure 1B), 
in agreement with previous observations 
(Goldberg et al., 2007). Conversely, TGF-β1 
reduced the expression of the epithelial 
marker E-cadherin further in A549 and 
H1975, whereas H441 and PC9 cells re-
tained high/moderate E-cadherin expres-
sion levels (Figure 1, A and B, and Supple-
mental Figure S1). The down-regulation of 
E-cadherin by TGF-β1 in A549 cells was fur-
ther confirmed by Western blotting (Supple-
mental Figure S1). In contrast, primary myo-
fibroblasts were negative for E-cadherin. On 
the other hand, the absolute intensity values 
of vimentin fluorescence after TGF-β1 treat-
ment shown in Figure 1C were somewhat 
cell line (in epithelial cells) and patient (in 
fibroblasts) dependent, which may be asso-
ciated with the particular genetic alterations 
of each cell line and the intrinsic patient vari-
ability, respectively, as well as with potential 
limitations in our image processing. Yet, de-
spite the strong EMT phenotype in A549 
and H1975 cells supported by the large fold 
induction of vimentin (Figure 1B), their corresponding absolute vi-
mentin levels in the presence of TGF-β1 were less than half of those 
found in IPF fibroblasts and control fibroblasts activated with TGF-β1 
as shown in Figure 1C. In addition, TGF-β1 treatment held the num-
ber of primary fibroblasts; likewise, it maintained or decreased 
the population of epithelial cells in a cell-line–dependent manner 
EMT, and there is extensive evidence that major EMT hallmarks are 
shared between normal epithelial cells during development and se-
lected transformed cells (Moreno-Bueno et al., 2009). Furthermore, 
the A549 cell line in particular is a widely used model of alveolar 
epithelial-like behavior in noncancer-oriented studies (Lieber et al., 
1976). To provide cells a profibrotic microenvironment, both epithe-
FIGURE 1: Immunofluorescence analysis of epithelial (E-cadherin) and mesenchymal (vimentin) 
markers in EMT-competent lung epithelial cells and primary lung fibroblasts. (A) Representative 
immunofluorescence images of E-cadherin (left) and vimentin (right) in epithelial cell lines (H441, 
A549) and primary fibroblasts obtained from randomly selected control (fibrosis-free) or IPF 
patients (referred by the three-digit number following # symbol) cultured for 3 d in the absence 
or presence of 5 ng/ml TGF-β1. Images were obtained with a ×20 objective (seven images/
condition). Blue indicates DAPI staining here and thereafter. Scale bar here, 50 μm. 
Representative images from other epithelial cell lines (PC9, H1975) and patients are shown in 
Supplemental Figure S1. (B) Ratio of the average vimentin fluorescence intensity per cell 
obtained in the presence or absence of TGF-β1 in a panel of epithelial cell lines and primary 
fibroblasts from randomly selected control and IPF patients. Horizontal gray dashed line 
corresponds to no fold change (ratio = 1), whereas horizontal solid blue lines correspond 
to the average values for each cellular model (i.e., epithelial cells exhibiting weak or strong 
EMT, n = 2; and primary fibroblasts from control or IPF patients, n = 3). (C) Absolute average 
vimentin fluorescence intensity per cell obtained on stimulation with TGF-β1 in the same cell 
models shown in B. *p ≤ 0.05 with respect to 1 were determined by Student’s t test (here and 
hereafter).
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(Figure 2A and Supplemental Figure S3). On 
TGF-β1 stimulation, A549 cells scattered and 
exhibited a lower value of circularity (adimen-
sional index constrained between 0 and 1, 
where 1 corresponds to a perfect circle) and a 
higher elongation (ratio between cell length 
and width) and spreading (cell projected 
area) than H441 cells (Figure 2, B–D). The 
shape changes elicited by TGF-β1 in A549 
are hallmarks of EMT (Moreno-Bueno et al., 
2009; O’Connor and Gomez, 2014) and were 
also observed in H1975 but not in PC9. 
Spreading analysis revealed a progressive in-
crease in the average cell area in cells under-
going EMT (∼1500 μm2), control myofibro-
blasts (∼2500 μm2), and IPF myofibroblasts 
(∼3000 μm2) (Figure 2D). The latter differ-
ences in spreading attained statistical signifi-
cance between each EMT model compared 
with both sources of primary myofibroblasts 
but not between IPF and control myofibro-
blasts (Figure 2D).
Likewise, all morphological parameters 
were statistically different between weak 
and strong EMT models (p < 0.05, Student’s 
t test) but not between control and IPF 
fibroblasts. However, to address our main 
goal (i.e., compare different EMT models 
with fibroblasts), and for the sake of simplic-
ity, we reduced two-group comparisons to 
those between different EMT models and 
fibroblasts only. Of note, the morphological 
differences between cells undergoing EMT 
and primary fibroblasts stimulated with 
TGF-β1 were even more dramatic and sta-
tistically significant in terms of elongation 
and circularity than of spreading. Collec-
tively, these results indicate that TGF-β1 in-
duces a mesenchymal-like phenotype in 
EMT-competent cells but fails to match the 
vimentin expression and morphological fea-
tures of activated primary fibroblasts.
TGF-β1 induces a robust assembly of α-SMA into stress 
fibers in primary fibroblasts but not in cells undergoing EMT
The primary marker of the myofibroblast phenotype in vitro is the 
expression of α-SMA and its assembly into a cytoskeleton rich in 
stress fibers (Tomasek et al., 2002). In addition, some authors have 
described an intermediate phenotype between a nonactivated fi-
broblast and a myofibroblast characterized by the prominent pres-
ence of stress fibers containing little or no α-SMA and have referred 
to it as proto-myofibroblast (Tomasek et al., 2002; Hinz, 2012). To 
visualize simultaneously both the actin cytoskeleton and α-SMA, we 
immunostained cells cultured as in the previous experiments for 
both F-actin and α-SMA, as shown in Figure 3 and Supplemental 
Figure S4, and performed two complementary colocalization analy-
ses with ImageJ (Abramoff et al., 2004). First, we computed the 
Manders colocalization coefficient M(α-SMA), which measures the 
fraction of α-SMA co-occurring with F-actin staining (Manders et al., 
1993). This coefficient is constraint between 0 (absence) and 1 (com-
plete colocalization) and is considered the most biologically relevant 
quantitative assessment of colocalization (Dunn et al., 2011). As 
(Supplemental Figure S2), in agreement with previous results 
(Wang et al., 2015). These observations are consistent with the 
universal cytostatic effects and selective apoptotic function of 
TGF-β1 in epithelial cells (Siegel and Massague, 2003). All these 
results on epithelial cells are consistent with previous observations 
(Yauch et al., 2005; Yamaguchi et al., 2017) and support that 
TGF-β1 elicits a strong EMT phenotype in A549 and H1975 cells 
but not in H441 and PC9 cells. Accordingly, these cell lines were 
used as models of strong (A549, H1975) and weak (H441, PC9) 
EMT thereafter.
A common feature of EMT is a morphological change in which epi-
thelial cells exhibit an elongated fibroblast-like shape (Moreno-Bueno 
et al., 2009). To assess to what extent the shape of epithelial cell lines 
stimulated with TGF-β1 resembled that of actual lung fibroblasts, we 
conducted a morphometric analysis of phase contrast images of cells 
on a 3-d treatment with TGF-β1. In the absence of exogenous TGF-β1, 
both H441 and A549 cells exhibited cell–cell adhesions and a round-
ish shape with limited spreading, whereas all primary (nonactivated) 
fibroblasts exhibited the usual spindle shape and marked elongation 
FIGURE 2: Morphometric analysis of EMT-competent lung epithelial cells and primary lung 
fibroblasts stimulated with the profibrotic cytokine TGF-β1 for 3 d. (A) Representative phase 
contrast images of epithelial cells (H441, A549) and primary fibroblasts obtained from randomly 
selected control or IPF patients in the absence or presence of TGF-β1. Images were obtained 
with a ×20 objective (two to three images/condition). Scale bar, 50 μm. Representative images 
from other epithelial cell lines (PC9, H1975) and patients are shown in Supplemental Figure S3. 
(B–D) Average cell values of the circularity (B), elongation (C), and spreading (D) assessed on 
stimulation with TGF-β1 in epithelial cells undergoing weak or strong EMT and in primary 
fibroblasts from control or IPF patients. On average, 30 cells were analyzed per experimental 
condition. *p ≤ 0.05, **p ≤ 0.01, and ***p ≤ 0.005 with respect to IPF fibroblasts; #p ≤ 0.05, 
##p ≤ 0.01, and ###p ≤ 0.005 with respect to control fibroblasts. All comparisons were determined 
by Student’s t test.
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consistent with the percentages of α-SMA 
positive cells reported in primary lung fi-
broblasts obtained from the same type of 
IPF and control (fibrosis-free) patients else-
where (Gabasa et al., 2013).
Given the importance of F-actin in cell 
mechanics (Alcaraz et al., 2017), we also 
analyzed quantitatively F-actin fluores-
cence stainings. Unlike vimentin stainings, 
we observed a similar average F-actin in-
tensity in all EMT models (i.e., weak and 
strong) in response to 5 ng/ml TGF-β1 that 
was approximately fourfold lower than the 
F-actin intensity obtained in both control 
and IPF myofibroblasts (Figure 4C). Collec-
tively these observations reveal that EMT-
competent lung cells do not exhibit stan-
dard cytoskeletal markers indicative of well 
differentiated myofibroblasts when stimu-
lated with TGF-β1 in vitro.
Potential relative contribution of 
epithelial cells and fibroblasts to the 
stiff microenvironment in IPF
The stiff microenvironment that character-
izes IPF and other fibrotic disorders has been 
largely associated with the enhanced con-
tractile properties of myofibroblasts and 
their excessive deposition of fibrillar colla-
gens (King et al., 2011; Hinz, 2012; Ho et al., 
2014). To assess the relative contribution of cells undergoing EMT to 
such stiff microenvironment in the context of IPF at the cellular level, 
we first measured cell stiffening in response to TGF-β1 by nanoin-
dentation measurements with AFM, which enables computing the 
local Young’s modulus (E) of single cells (Alcaraz et al., 2003). E is a 
standard physical parameter that describes the resistance of a sam-
ple to the deformation imposed by a low/moderate external loading 
force, and is widely used to characterize the mechanical properties of 
cells and other biological samples (Butcher et al., 2009; Giménez 
et al., 2017b). In addition, we previously reported that E measure-
ments are good indicators of cellular contractility (Roca-Cusachs 
et al., 2008). During each nanonindentation measurement, a cantile-
ver force sensor provided with a micrometer sized pyramidal blunted 
tip—exhibiting a radius of curvature at the apex of ∼20 nm—was 
brought into contact with the cell surface (Figure 5A) and used to 
apply an increasing loading force up to ∼1 nN while monitoring cell 
resistance to deformation. These conditions elicited a maximum tip-
cell contact area (∼0.1–0.2 μm2), which is approximately three orders 
of magnitude lower than cell spreading data (Figure 2D), thereby 
probing the local mechanical properties of the cell. Caution was 
taken to perform nanoindentation measurements at the perinuclear 
region and at low/moderate relative indentations to probe the me-
chanics of the cytoskeleton while minimizing contributions of the 
nucleus and the underlying tissue culture plastic (Roca-Cusachs 
et al., 2008; Giménez et al., 2017b). E data for each cell line and pa-
tient are shown in Supplemental Figure S5. To assess cell stiffening, 
we computed the ratio of E measured in the presence or absence of 
TGF-β1. As shown in Figure 5B, TGF-β1 stiffened all epithelial cell 
models in a cell-line–dependent manner but PC9, which may be as-
sociated with the particular genetic alterations of this cell line (see 
the Supplemental Material for an extended discussion). However, the 
largest cell stiffening elicited by TGF-β1 was consistenly observed in 
shown in Figure 4A, the average M(α-SMA) values on TGF-β1 stimu-
lation were similarly very high in both IPF fibroblasts and control fi-
broblasts (>0.95) compared with epithelial cells exhibiting either 
strong (∼0.8) or weak (∼0.7) EMT. The M(α-SMA) values of each EMT 
model (but not in control fibroblasts) were statistically different than 
those of IPF fibroblasts. These results reveal that EMT failed to 
match the colocalization found in activated primary fibroblasts.
Since M(α-SMA) values capture global rather than specific colo-
calization of α-SMA into stress fibers, we conducted a second (quali-
tative) visual colocalization analysis with ImageJ based on highlight-
ing in white overlapping F-actin and α-SMA stainings as shown in 
Figure 3 and Supplemental Figure S4. This visual analysis revealed 
abundant white straight lines suggestive of α-SMA aligned into ac-
tin stress fibers in both control and IPF fibroblasts on TGF-β1 stimu-
lation, whereas such white straight lines were much less abundant or 
largely absent in epithelial cells exhibiting strong or weak EMT, re-
spectively. In an attempt to relate these colocalization images with 
the appearance of the myofibroblast phenotype, those cells exhibit-
ing at least three straight and continous white (colocalization) 
straight lines were taken as apparent well-differentiated myofibro-
blasts, whereas cells that did not fulfill the latter criteria but exhib-
ited at least three straight but discontinuous white lines (not speck-
led/noisy looking) were counted as proto-myofibroblast–like cells. 
The latter colocalization analysis revealed a progressive increase in 
the percentage of apparent proto-myofibroblasts in cells undergo-
ing EMT (∼5%), control fibroblasts (∼15%), and IPF fibroblasts (∼20%) 
on 3-d stimulation with TGF-β1. In contrast, apparent well-differen-
tiated myofibroblasts were observed in both control and IPF fibro-
blasts to a similar extent (∼40%), but they were largely absent in 
EMT models (Figure 4B). Adding the percentages of apparent 
proto-myofibroblasts and well-differentiated myofibroblasts elicited 
an average ∼60% value in both control and IPF fibroblasts, which is 
FIGURE 3: Visualization of the actin cytoskeleton, α-SMA, and their colocalization on 
stimulation with TGF-β1 for 3 d. Selected regions from representative immunofluorescence 
images of F-actin (left), α-SMA (middle), and their corresponding colocalization (right) in 
epithelial cells (H441, A549) and primary fibroblasts obtained from randomly selected control or 
IPF patients cultured in the absence or presence of 5 ng/ml TGF-β1. The colocalization of F-actin 
and α-SMA was labeled in white. Images were obtained with a ×20 objective (seven images/
condition). Scale bar, 50 μm. Full images as well as additional representative images from other 
epithelial cell lines (PC9, H1975) and patients are shown in Supplemental Figure S4.
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IPF fibroblasts (∼3-fold on average), whereas TGF-β1 induced only a 
modest cell stiffening in control fibroblasts (∼1.5-fold) (Figure 5B).
To better compare the potential contribution of EMT cells and 
myofibroblasts to tissue stiffness, we plotted the absolute E values 
of single cells recorded after 3 d of TGF-β1 stimulation concomi-
tantly with a horizontal band spanning the physiologic range of E 
data from pulmonary tissue (∼2–10 kPa) reported elsewhere (Ebihara 
et al., 2000; Liu et al., 2010; Brown et al., 2013) in Figure 5C. Al-
though we observed a progressive increase in E in cells undergoing 
EMT (∼5 kPa), control myofibroblasts (∼8 kPa) and IPF myofibro-
blasts (∼13 kPa), their average E values were beyond the physiologic 
range in IPF myofibroblasts only (Figure 5C). Interestingly, the differ-
ence in E values observed in control and IPF myofibroblasts was 
statistically significant, supporting our initial observation of larger 
cell stiffening in myofibroblasts from IPF patients compared with 
those from control donors (Figure 5B). Likewise, E values of epithe-
lial cells undergoing EMT were also different from E values obtained 
in either control or IPF fibroblasts with statistical significance. In ad-
dition we noticed that the differences in the average E values of cells 
undergoing EMT and primary myofibroblasts were much lower than 
the differences between other parameters examined in this study 
that had been previously pointed to as regulators of cell stiffness, 
including spreading (Figure 2D), F-actin (Figure 4C), and apparent 
myofibroblast enrichment (Figure 4, A and B) (Roca-Cusachs et al., 
2008; Hinz, 2012). These observations suggest that the mechanical 
differences between epithelial cells undergoing EMT and myofibro-
blasts are due to other unidentified factors.
We next analyzed the expression of type I and type III collagens, 
which are the most abundant fibrillar collagens that are also fre-
quently used as myofibroblast and EMT markers, respectively 
(Forino et al., 2006; Hinz et al., 2012). For this purpose, we assessed 
the mRNA levels of COL1A1 and COL3A1 genes by quantitative 
reverse transcription PCR (qRT-PCR) in cells stimulated with TGF-β1 
for 3 d as in the previous experiments. In agreement with cell me-
chanical data, the expression of both COL1A1 and COL3A1 was 
moderately higher (35 and 25%, respectively) in myofibroblasts from 
IPF patients compared with those from control donors, and this dif-
ference attained statistical significance (Figure 6, A and B). In con-
trast, the expression of these genes in epithelial cells undergoing 
EMT was 3 orders of magnitude lower than in myofibroblasts. Inter-
estingly, the expression of COL3A1 (but not COL1A1) in epithelial 
cells exhibiting a weak EMT was 3 orders of magnitude lower than 
those exhibiting strong EMT, providing additional support that 
COL3A1 is a suitable EMT marker (Forino et al., 2006). To validate 
the differences in the mRNA levels of fibrillar collagens between 
myofibroblasts from IPF and control patients at the protein level, we 
assessed the total amount of secreted collagen (types I–V) in the 
culture medium of primary fibroblasts stimulated with TGF-β1 for 3 
d using the Sircol collagen assay as shown in Figure 6C. Total se-
creted collagen was ∼25% higher in myofibroblasts from IPF com-
pared with control patients, which is very close to the ∼35% and 
FIGURE 4: Assembly of α-SMA into stress fibers in EMT-competent 
lung epithelial cells and primary lung fibroblasts on stimulation with 
TGF-β1 for 3 d. (A) Quantitative colocalization analysis of the images 
in Figure 3 through the Manders colocalization coefficient M(α-SMA), 
which corresponds to the fraction (between 0 and 1) of α-SMA 
co-occurring with F-actin. (B) Colocalization analysis of the images in 
Figure 3 in terms of the percentage of cells stimulated with TGF-β1 
that exhibited at least three straight and continuous white lines (green 
bars) or three straight and discontinuous (but not speckled) white 
lines (red bars), which were interpreted as apparent (well-
differentiated) myofibroblasts or proto-myofibroblasts, respectively. 
(C) Absolute average F-actin fluorescence intensity per cell obtained 
on stimulation with TGF-β1 in epithelial cells undergoing weak or 
strong EMT and in primary fibroblasts from either control or IPF 
patients. Statistical analysis as in Figure 2.
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∼25% increases in COL1A1 and COL3A1 mRNA expression in the 
former cells, respectively.
Combining the mechanical and collagen expression data sup-
ports that myofibroblasts are the larger contributors to the stiff mi-
croenvironment in terms of both cell stiffness and expression of fibril-
lar collagens. Moreover, to the best of our knowledge, our results 
show for the first time that the contribution of epithelial cells under-
going EMT to the stiff microenvironment may be relevant in terms of 
cell stiffness but not of expression of fibrillar collagens. In addition, 
our measurements reveal that myofibroblasts derived from IPF pa-
tients exhibit aberrant mechanobiology responses to TGF-β1 in 
terms of both cell stiffness and expression of fibrillar collagens, which 
may be a critical contributor of the profibrotic tissue stiffening in IPF.
Once elucidated that EMT fails to induce a myofibroblast-like 
phenotype in our cell models in vitro, we wondered whether EMT 
may induce bona fide traits of nonactivated fibroblasts. For this pur-
pose, we compared the average values of all the parameters exam-
ined throughout this work in both EMT-competent cells stimulated 
with TGF-β1 and in (nonactivated) fibroblasts from control donors 
cultured in the absence of TGF-β1. As shown in Figure 7, cells un-
dergoing EMT could be distinguished from nonactivated primary 
fibroblasts in all parameters but spreading, exhibiting the largest 
differences in terms of vimentin (Figure 7A), morphology (elonga-
tion, circularity) (Figure 7, E and F), and expression of both COL1A1 
and COL3A1 (Figure 7, H and I).
FAKY397 activity is enhanced in IPF fibroblasts compared 
with control fibroblasts stimulated with TGF-β1, which 
may underlie the larger stiffness and collagen expression 
of the former
Prompted by the enhanced stiffness and expression of fibrillar col-
lagens of IPF fibroblasts compared with control fibroblasts on 
TGF-β1 stimulation, we began to examine potential underlying 
mechanisms. Focal adhesion kinase (FAK) is an important regulator 
of the bidirectional cell-ECM mechanical interactions in fibroblasts 
and other cell types through its phosphorylation at Y397, which is 
also upregulated by TGF-β1 (Thannickal et al., 2003; Mitra et al., 
2005; Ho et al., 2014). Interestingly, previous in vivo studies revealed 
that FAKY397 activity is enhanced within fibroblast foci in IPF patients 
(Cai et al., 2010; Lagares et al., 2012; Ding et al., 2013), and its 
forced down-regulation protected against bleomycin-induced lung 
fibrosis in mice (Lagares et al., 2012; Zhao et al., 2016). To examine 
FAKY397 activity in our in vitro models, we first identified a suitable 
timing on TGF-β1 stimulation by conducting a time-course experi-
ment in control fibroblasts (Figure 8A). Western blot analysis re-
vealed a peak in FAKY397 at ∼6 h, which is in agreement with previous 
studies (Thannickal et al., 2003) and was used thereafter. Of note, 
FAKY397 activity was increased approximately twofold in IPF fibro-
blasts compared with control fibroblasts following TGF-β1 treat-
ment (Figure 8B). To assess whether enhanced FAK activity is suffi-
cient to increase fibroblast stiffness and/or expression of fibrillar 
FIGURE 5: Nanoindentation elasticity measurements of single cells 
carried out with AFM on lung epithelial cells and primary lung 
fibroblasts. (A) Representative phase contrast image of an AFM force 
sensor (cantilever) on top of a single lung epithelial cell (A549). AFM 
force sensors were used to indent locally the cell surface and assess 
the corresponding opposing force to compute the Young’s modulus 
(E) as described in Material and Methods, using three technical 
replicates. (B) Ratio of the average E values obtained on single cells 
cultured in the presence or absence of TGF-β1 in a panel of epithelial 
cell lines (n = 4) and primary fibroblasts from randomly selected 
control (n = 5) and IPF (n = 5) patients. On average 10 cells were 
measured per experimental condition (two independent experiments). 
Horizontal gray dashed line corresponds to no fold change (ratio = 1), 
whereas horizontal solid blue lines correspond to the average values 
for each cellular model (i.e., epithelial cells exhibiting weak or strong 
EMT, and primary fibroblasts from control or IPF patients) as in 
Figure 1B. The E data for each cell line and patient are shown in 
Supplemental Figure S5. Statistical analysis as in Figure 1B. 
(C) E values obtained on single cells on TGF-β1 stimulation from 
each cellular model. Red horizontal lines correspond to the average 
E values for each model as in Figure 1C. The semi-transparent orange 
horizontal band corresponds to the E values assessed on normal 
pulmonary tissue elsewhere (see the main text for references) and was 
added to illustrate the aberrant mechanical behavior of IPF 
fibroblasts. Statistical analysis as in Figure 2.
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collagens, we took advantage of a well-established FAK cell model 
based on mouse embryonic fibroblasts that are either wild type 
(FAK+/+) or FAK null (FAK–/–) (Lagares et al., 2012). As expected, 
TGF-β1 increased FAKY397 activity in FAK+/+ fibroblasts, whereas the 
expression of both total FAK and FAKY397 were largely absent in 
FAK–/– fibroblasts (Figure 8C). Likewise, AFM analysis reported ∼60% 
larger average E values in FAK+/+ compared with FAK–/– fibroblasts 
(Figure 8D), which was associated with a larger percentage of α-
SMA colocalized with F-actin in the former as revealed by immuno-
fluorescence (Figure 8E). In agreement with AFM data, qRT-PCR 
measurements showed a strikingly higher expression of both Col1a1 
and Col3a1 mRNA levels in FAK+/+ compared with FAK–/– fibroblasts 
on TGF-β1 stimulation (Figure 8, F and G). Taken together, and to 
the best of our knowledge, these observations report for the first 
time a larger FAKY397 activity in TGF-β1-activated fibroblasts derived 
from IPF patients compared with control patients, and strongly sup-
port that such FAKY397 hyperactivation may be a driving mechanism 
underlying the aberrant mechanobiology of IPF fibroblasts, at least 
in terms of cell stiffness and expression of fibrillar collagens.
DISCUSSION
It is increasingly acknowledged that the chronic stiffening of the tis-
sue microenvironment observed in IPF and other fibrotic disorders 
provides profibrotic cues that are essential for the progression of 
organ fibrosis (Hinz, 2012; Ho et al., 2014). Myofibroblasts are 
pointed to as critical effector cells in both tissue stiffening and fibro-
sis progression in the lung and other organs (King et al., 2011; Hinz, 
2012; Ho et al., 2014). Yet it remains controversial what the contribu-
tion of epithelial cells undergoing EMT is to tissue stiffening and 
overall myofibroblast population (Bartis et al., 2014; O’Connor and 
Gomez, 2014). By examining a panel of commonly used lung EMT 
models, we found evidence supporting that lung cells undergoing 
EMT may contribute to the profibrotic stiff microenvironment 
through their enhanced endogenous stiffness but not through their 
expression of fibrillar collagens. In addition, we found that EMT ren-
ders a phenotype that is clearly different from that of myofibroblasts 
derived from IPF patients in terms of mechanics, collagen expres-
sion, morphology, and cytoskeletal organization. Indeed, cells un-
dergoing EMT could be easily distinguished even from nonactivated 
fibroblasts, thereby challenging the ability of EMT to provide myofi-
broblast precursors further, unlike previously suspected (Kim et al., 
2006; Willis et al., 2006; Degryse et al., 2010; Yamaguchi et al., 
2017). Conversely, the responses of fibroblasts derived from control 
(fibrosis-free) donors—which were used to model resident fibro-
blasts—to the profibrotic cytokine TGF-β1 were similar to those of 
myofibroblasts derived from IPF patients in all the parameters ex-
amined. Accordingly, our data support that myofibroblasts in IPF are 
directly populated largely from resident fibroblasts (Rock et al., 
2011; Giannandrea and Parks, 2014). In contrast, EMT may contrib-
ute indirectly to the myofibroblast population in IPF by perturbing 
normal parenchymal architecture (through loss of cell–cell adhe-
sions required for alveolar integrity) and by providing profibrotic 
cytokines, in agreement with previous observations in mouse mod-
els of pulmonary fibrosis or renal fibrosis on induction of partial EMT 
(Wu et al., 2007; Kim et al., 2009; Grande et al., 2015).
Previous AFM mechanical measurements in the context of pul-
monary fibrosis have been limited to whole and decellularized tis-
sue sections (Liu et al., 2010; Melo et al., 2014; Alcaraz et al., 
2017), whereas no studies have been conducted on IPF fibroblasts. 
Likewise, most previous EMT studies have focused on the expres-
sion of epithelial and mesenchymal markers, whereas studies ex-
amining the corresponding mechanical alterations had been 
FIGURE 6: Expression of fibrillar collagens in EMT-competent lung 
epithelial cells and primary lung fibroblasts on stimulation with 
TGF-β1 for 3 d. (A, B) mRNA levels of COL1A1 (A) and COL3A1 
(B) assessed by qRT-PCR using three technical replicates. POLR2A 
was used as endogenous gene. (C) Total secreted collagens of primary 
myofibroblasts assessed with the Sircol assay. Statistical analysis as in 
Figure 2. Note the vertical log scale in A and B.
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age up to fourfold in response to TGF-β1, although their average 
E was ∼50% lower than that of control fibroblasts. Such a range of 
cell stiffening is in agreement with the twofold increase in E of 
A549 cells measured by AFM on treatment with 5 ng/ml TGF-β1 
for 48 h elsewhere (Buckley et al., 2012) and with the fivefold stiff-
ening reported in mouse mammary epithelial cells stimulated with 
10 ng/ml TGF-β1 for 48 h (Schneider et al., 2013). To the best of 
scarce (Moreno-Bueno et al., 2009; Buckley et al., 2012; Bartis 
et al., 2014). Remarkably, our AFM measurements revealed that 
the average cell stiffness (E) of IPF myofibroblasts was beyond the 
physiologic range of pulmonary tissue stiffness, whereas that of 
myofibroblasts from control donors was not, underscoring the ab-
errant mechanical behavior of IPF myofibroblasts. Moreover, we 
found that a panel of lung cells undergoing EMT stiffened on aver-
FIGURE 7: Comprehensive comparison of the phenotype of lung cells undergoing EMT on stimulation with TGF-β1 and 
that of nonactivated primary fibroblasts from control donors cultured in the absence of TGF-β1 in terms of vimentin (A), 
F-actin (B), % of apparent proto-myofibroblasts/myofibroblasts (C), spreading (D), circularity (E), elongation (F), stiffness 
(G), and expression of COL1A1 (H) and COL3A1 (I). Statistical analysis as in Figure 2.
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FIGURE 8: Analysis of FAKY397 activity in primary fibroblasts on TGF-β1 stimulation, and effect of loss of FAK activity in 
the stiffness, cytoskeletal organization, and collagen expression of fibroblasts. (A) Representative Western blot showing 
the time-course expression of FAKY397, total FAK, and β-actin in primary control fibroblasts stimulated with TGF-β1. 
(B) Representative Western blot showing FAKpY397 and total FAK of control fibroblasts and IPF fibroblasts stimulated 
with TGF-β1 for 6 h; right: corresponding densitometry analysis of FAKpY397/FAK in control (n = 4) and IPF fibroblasts 
(n = 4). (C) Representative Western blot showing FAKpY397, total FAK and α-tubulin of FAK wild-type (FAK+/+), or FAK null 
(FAK–/–) mouse embryonic fibroblasts stimulated with TGF-β1 for 6 h; right: corresponding densitometry analysis of 
FAKpY397/α-tubulin (n = 3). (D) E of FAK+/+ and FAK–/– fibroblasts stimulated with TGF-β1 for 3 d assessed by AFM as in 
Figure 5. (E) Selected regions from representative immunofluorescence images of F-actin (left), α-SMA (middle), and 
their corresponding colocalization (right) of FAK+/+ and FAK–/– fibroblasts stimulated with TGF-β1 for 3 d. Images were 
obtained as in Figure 3. Scale bar, 50 μm. (F, G) mRNA levels of Col1a1 (F) and Col3a1 (G) of FAK+/+ and FAK–/– 
fibroblasts stimulated with TGF-β1 for 3 d assessed as in Figure 6. Statistical analysis as in Figure 2 (n = 2, unless 
otherwise indicated).
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and even hindering the diffusion of molecular therapeutics (Egeblad 
et al., 2010; Galgoczy et al., 2014). Conversely, all these observa-
tions strongly suggest that restoring normal collagen homeostasis 
may be a useful therapeutic strategy in organ fibrosis. In support of 
this hypothesis, we and others have reported that nintedanib—a 
recently approved drug to treat IPF—markedly reduces collagen ex-
pression by fibroblasts in vitro and in vivo (Hostettler et al., 2014; 
Wollin et al., 2014; Gabasa et al., 2017).
Remarkably, our in vitro analysis revealed modest yet signifi-
cantly larger responses to TGF-β1 in fibroblasts derived from IPF 
patients compared with control donors in terms of both cell stiffness 
and expression of fibrillar collagens. Likewise, TGF-β1 elicited larger 
FAKY397 activity in IPF fibroblasts compared with control fibroblasts, 
thereby expanding previous histologic observations of enhanced 
FAKY397 expression within fibroblast foci in IPF samples (Cai et al., 
2010; Lagares et al., 2012; Ding et al., 2013). On the other hand, we 
found that FAK depletion in fibroblasts was sufficient to markedly 
reduce both the stiffness and expression of fibrillar collagens in re-
sponse to TGF-β1, concomitantly with a decrease in α-SMA colocal-
ized with actin stress fibers. In agreement with our findings, a previ-
ous study on the FAK-related nonkinase protein FRNK, which is an 
independently expressed protein that negatively regulates FAK, re-
ported its down-regulation in IPF samples; moreover, genetic down-
regulation of FRNK in mouse fibroblasts was sufficient to increase 
FAKY397 concomitantly with collagen expression, contractility, and 
α-SMA in response to TGF-β1 (Ding et al., 2013). Unlike cell stiffness 
and collagen expression, we could not detect statistically significant 
differences between IPF fibroblasts and control fibroblasts in terms 
of F-actin content and its colocalization with α-SMA. The latter neg-
ative observations may reflect either lack of sufficient resolution in 
our immunofluorescence quantitative approaches or that the aber-
rant mechanical features of IPF myofibroblasts are due to other cy-
toskeletal associated proteins. Taken together, these novel observa-
tions support that FAKY397 hyperactivation in IPF fibroblasts may be 
a driving mechanism of the aberrant mechanobiology of these cells. 
Moreover, they support that targeting FAKY397 could be a suitable 
therapeutic approach aiming to restore normal fibroblast mechano-
biology in IPF. In support of these interpretations, both pharmaco-
logic and genetic inhibition of FAK activity protected against bleo-
mycin-induced lung fibrosis in mice (Lagares et al., 2012; Zhao et al., 
2016).
In summary, our study sheds light on the controversial contribu-
tion of EMT to the increased myofibroblast population in IPF. In 
addition, our work provides evidence supporting the direct patho-
logic contribution of IPF myofibroblasts to the stiff microenviron-
ment in IPF through their own aberrant stiffness and excessive ex-
pression of fibrillar collagens, and reveals that such aberrant 
mechanobiology is associated with FAKY397 hyperactivation. More-
over, our results support that EMT may contribute to tissue stiffen-
ing by increasing epithelial cell stiffness, although to a lesser ex-
tent than myofibroblasts, but not through collagen deposition. 
Our results underscore also the remarkable potential of TGF-β1 to 
increase tissue stiffness through its direct impact on cell stiffness 
and collagen expression in the context of an already stiff microen-
vironment. These novel insights may help in designing future ther-
apeutic studies aiming to restore normal mechanobiology in IPF 
(Ho et al., 2014).
MATERIAL AND METHODS
Isolation of adult human lung fibroblasts
Primary fibroblasts were isolated in sterile conditions by outgrowth 
of tissue explants from pulmonary tissue as described elsewhere 
our knowledge, our observations provide the first direct evidence 
of the mechanical diffences between cells undergoing EMT and 
myofibroblasts probed by AFM, and support that the contribution 
of the former to the tissue stiffening in IPF cannot be neglected, 
even though it is lower than that of myofibroblasts.
Most of the few previous attempts to examine the responses of 
normal lung epithelial cells to TGF-β have used type II alveolar epi-
thelial cells (AECs) derived from rodents (Zhang et al., 2004; Willis 
et al., 2005; Bhaskaran et al., 2007; Zhao et al., 2013). These studies 
have consistently reported anti-proliferative effects of TGF-β1, 
which were also observed in the four epithelial cell lines used here. 
Likewise, a previous study of EMT induction by TGF-β1 on rat AECs 
reported common EMT hallmarks (i.e., down-regulation of epithe-
lial markers, a fibroblast-like morphology, and an up-regulation of 
mesenchymal markers, including vimentin, type I collagen, and α-
SMA) (Willis et al., 2005) that are reminiscent of our observed EMT 
induction elicited by TGF-β1 in selected cell lines (A549 and H1975). 
The latter similarity is unsurprising considering that EMT hallmarks 
have been reported in both normal epithelial cells during develop-
ment and in pathologic conditions including organ fibrosis and can-
cer (Moreno-Bueno et al., 2009). Thus, even though the molecular 
underpinnings underlying TGF-β1 responses may be altered during 
malignant transformation (particularly in PC9 cells), the consistently 
similar responses to TGF-β1 in terms of cytostasis, stiffening, and 
expression of EMT markers compared with normal rodent epithelial 
cells reported elsewhere support that the former were a reasonable 
experimental model to address the aims of this study.
The enhanced cellular stiffening of both IPF myofibroblasts and 
selected epithelial cells undergoing EMT may have important profi-
brotic consequences. First, it may increase directly tissue rigidity 
through the expected enhanced traction forces and ECM adhesion 
strength of both cell types (Roca-Cusachs et al., 2008; Acerbi et al., 
2012; Vizoso et al., 2015), which is in agreement with the critical 
mechanical roles of fibroblasts during the final contraction of a 
wound closure (Singer and Clark, 1999) and on the mechanical 
strength of fibroblast-populated three-dimensional collagen gels 
(Wakatsuki et al., 2003; Gehler et al., 2009). Moreover, cell stiffening 
may contribute indirectly to tissue stiffening by increasing the activa-
tion of extracellular TGF-β1, for there is growing evidence that such 
activation requires intracellular tension (Hinz, 2012; O’Connor and 
Gomez, 2014). Since matrix stiffness and TGF-β1 can cooperate to 
activate fibroblasts and promote EMT, all these observations sup-
port that cell stiffening contributes to a vicious cycle in which matrix 
stiffening activates fibroblasts and promotes EMT, which in turn in-
crease tissue stiffness further, thereby amplifying fibrosis (Liu et al., 
2010; Ho et al., 2014).
We previously showed that increasing the concentration of type 
I collagen or collagen cross-linking in acellular hydrogels was suffi-
cient to effectively increase gel stiffness as measured by AFM 
(Alcaraz et al., 2011; Vicens-Zygmunt et al., 2015; Gimenez et al., 
2017a). Based on the latter evidence and on the reported abundant 
deposition of fibrillar collagens and collagen crosslinkers concomi-
tantly with tissue stiffening in organ fibrosis (Barry-Hamilton et al., 
2010; Liu et al., 2010; King et al., 2011; Hinz, 2012; Ho et al., 2014), 
it is conceivable that the excessive and sustained expression of fi-
brillar collagens in fibrogenic myofibroblasts (but not in epithelial 
cells undergoing EMT) may directly contribute to the tissue stiffen-
ing in IPF. In addition, such excessive collagen expression may con-
tribute to IPF progression through other processes, including dis-
rupting normal alveolar architecture (Zeisberg et al., 2001), providing 
a profibrotic hypoxic microenvironment by hindering oxygen diffu-
sion (Moreno-Bueno et al., 2009; Colom et al., 2014; Ho et al., 2014) 
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terstained with DAPI (4′,6-diamidino-2-phenylindole; 1:10,000; 
Sigma). Slides were mounted with Prolong gold antifade reagent 
(Invitrogen). To quantify the fluorescence signal from a specifically 
labeled protein, slides were mounted on the motorized stage of the 
Eclipse TE2000 microscope (Nikon), and images were captured at 
seven randomized nonoverlapping locations with a ×20 objective 
and a cooled CCD camera (Orca AG) using Metamorph software 
(Molecular Devices). For each location, multiplex imaging was per-
formed by acquiring images corresponding to DAPI and protein 
staining using the same exposure time in subsaturation conditions. 
All quantitative image measurements were conducted with ImageJ. 
DAPI images were used to assess the number of cells per image. 
After background substraction, the average protein fluorescence 
intensity per cell was assessed by dividing the total intensity per 
image by the corresponding cell number and by averaging the val-
ues obtained in all locations. Nuclear counting of DAPI stainings 
were also used to assess the average cell number in the presence or 
absence of TGF-β1. Colocalization analysis of F-actin and α-SMA 
stainings was performed by using both the Manders coefficients 
and the colocalization highlighter plug-ins (ImageJ 1.41n).
qRT-PCR
Cells were plated in triplicate, and the corresponding total RNA was 
isolated using the RNeasy Mini kit (QIAGEN). A total of 1 μg of RNA 
was reverse transcribed into cDNA using the High Capacity cDNA 
Reverse Transcription Kit and RNase inhibitor (Applied Biosystems). 
Real-time PCRs were performed on 40 ng of each cDNA sample 
using TaqMan Gene Expression Master Mix and TaqMan gene-spe-
cific primer pairs and probes for human genes encoding collagen 
type I, alpha 1 (COL1A1) (Hs00164004_m1), collagen type III, alpha 
1 (COL3A1) (Hs00164103_m1), and the RNA polymerase II poly-
peptide A (POLR2A, used as a reference gene) (Hs00172187_m1), 
and for mouse genes encoding Col1a1 (Mm00801666_g1), Col3a1 
(Mm01254476_m1), and Polr2a (Mm00839502_m1, used as a refer-
ence gene) (Applied Biosystems). Reactions were carried out for 40 
cycles (95°C for 21 s and 60°C for 20 s) in a 7900HT Fast Real-Time 
PCR System (Applied Biosystems). Relative gene expression was as-
sessed using the comparative Ct method as described elsewhere 
(Livak and Schmittgen, 2001). In brief, a common threshold was de-
fined in the exponential phase of the PCR amplification curves for 
each gene, and the corresponding threshold cycles (Ct) were ob-
tained and averaged over each replicate. Relative gene expression 
with respect to POLR2A was assessed as k⋅2–ΔCt, where k is the ratio 
of the threshold numbers used for the target and the endogenous 
genes, respectively, and ΔCt is the difference between the average 
Ct of the target and the reference (endogenous) genes.
Sircol collagen assay
Total secreted soluble collagen (types I–V) in the culture medium 
of fibroblasts was assessed using the Sircol collagen assay as 
reported elsewhere (Gabasa et al., 2013). Briefly, culture me-
dium was collected for each experimental condition, concen-
trated, and stained with Sirius red dye to form a collagen-dye 
complex, which was precipitated and solubilized. The corre-
sponding absorbance was measured at 540 nm with a micro-
plate enzyme-linked immunosorbent assay (ELISA) reader, con-
verted into collagen concentration through a calibrated standard 
curve, and multiplied by each sample volume to assess the total 
secreted collagen in micrograms. Results were normalized to to-
tal protein content, which was measured with the Lowry assay. 
Final results are shown as secreted collagen (micrograms)/total 
protein (micrograms).
(Gabasa et al., 2013) and frozen stored in liquid nitrogen at pas-
sages 2 and 3 until use. This procedure was approved by the Ethics 
Committees of the Hospital Clínic de Barcelona and the Universitat 
de Barcelona. Histologically normal parenchymal tissue was ob-
tained from patients undergoing surgical pleurodesis to treat recur-
rent spontaneous pneumothorax (n = 9). IPF tissue was obtained 
from lung biopsies of patients exhibiting the histopathological pat-
tern of usual interstitial pneumonia (n = 8). Patients gave written in-
formed consent.
Cell culture and treatments
Before experiments, fibroblasts were fast thawed and grown in fi-
broblast culture media containing DMEM supplemented with 10% 
FBS (FBS Gold, PAA Laboratories), 100 IU/ml penicillin, 100 mg/ml 
streptomycin (Invitrogen), and 2 mg/ml amphotericin B (Sigma). All 
fibroblasts were used up to five to six passages to prevent replica-
tive senescence and guarantee their phenotypic stability (Chang 
et al., 2002; Lugo et al., 2016). H441 and A549 lung adenocarci-
noma cell lines were obtained from the American Type Culture Col-
lection (ATCC). PC9 and H1975 lung adenocarcinoma cell lines were 
kindly provided by Miquel Tarón (USP Dexeus University Institute, 
Barcelona, Spain), and their identity was confirmed in terms of ac-
cepted EGFR mutations (Blanco et al., 2009; van der Wekken et al., 
2016) as described elsewhere (Molina-Vila et al., 2008; Simonetti 
et al., 2010). Epithelial cells were maintained in culture medium con-
sisting of HEPES (Sigma)-buffered RPMI 1640 medium supple-
mented with 10% FBS, 1 mM l-glutamine (Invitrogen), and the same 
antibiotics as in fibroblasts. Mouse embryonic fibroblasts from wild-
type (FAK+/+) or FAK-deficient (FAK–/–) mice (ATCC) were cultured in 
DMEM as previously described (Lagares et al., 2012). All cultures 
were kept in a 5% CO2 humidified incubator at 37°C. For experi-
ments on tissue culture plastic or glass substrata, cells were seeded 
in the corresponding culture media until they reached ∼80% conflu-
ency (∼1 to 2 d), washed three times in phosphate-buffered saline 
(PBS), growth arrested in serum-free culture media (SFM) for 24 h, 
and treated for 3 d with SFM alone (used as control) or supple-
mented with 5 ng/ml human TGF-β1 (R&D Systems).
Bright-field optical microscopy
To assess major morphological features, cells were examined under 
an inverted optical microscope (Eclipse TE2000; Nikon) placed on a 
vibration isolation table (Isostation; Newport), using a ×20 objective 
and phase contrast optics. Phase contrast images were acquired with 
a cooled charge-coupled device (CCD) camera (Orca AG; Hama-
matsu Photonics). Cell spreading (A), elongation, perimeter (P), and 
circularity (C, computed as C = 4·π·A/P2) were assessed by manually 
tracing the boundary of single cells by ImageJ (Abramoff et al., 2004) 
as reported elsewhere (Roca-Cusachs et al., 2008; Lugo et al., 2016).
Fluorescence microscopy and image quantification
Cells were cultured on four-well chamber slides (BD Falcon) to ana-
lyze the expression of EMT and myofibroblast markers by immuno-
fluorescence. Slides were washed with PBS, fixed with cold 4% 
paraformaldehyde (Sigma) for 15 min, permeabilized with 0.5% 
Triton X-100 for 30 min, and blocked with 1% bovine serum albumin 
(BSA) in PBS for 1 h. Chamber slides were incubated for 1 h at 37°C 
with primary antibodies against either α-SMA (1:500), vimentin 
(1:100) (Invitrogen), or E-cadherin (1:100) (BD Biosciences). To de-
tect each primary antibody, chamber slides were washed with PBS 
and incubated with a suitable fluorescent secondary antibody for 
1 h at 37°C. F-actin was detected by incubating with tetramethyl-
rhodamine (TRITC)-phalloidin (Sigma) for 1 h. Nuclei were coun-
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Western blotting
Western blotting analysis of FAK activity was conducted as de-
scribed elsewhere (Puig et al., 2015). In brief, fibroblasts were 
lysed in extraction buffer supplemented with phosphatase and 
protease inhibitors. Equal protein amounts were separated on 10% 
Mini-PROTEAN TGX precast gels (Bio-Rad), transferred to a poly-
vinylidene difluoride (PVDF) membrane (GE Healthcare), blocked, 
and incubated overnight with suitable primary antibodies includ-
ing anti-FAK (3285; Cell Signalling), anti-FAKpY397 (700255; Invitro-
gen), anti–α-tubulin (5174 and 2144, Cell Signalling), or anti–β-
actin (Sigma). The latter two markers were used as loading 
controls. Protein bands were labeled and visualized by chemilumi-
nescence in a digital imaging system (ImageQuant LAS 4000; GE 
Healthcare). Protein band intensities were quantified with ImageJ 
and normalized to the corresponding loading control.
Single cell stiffness assessed from nanoindentation 
measurements with AFM
Cells were cultured on glass-bottomed 35-mm Petri dishes (MatTek) 
and placed on the stage of an inverted optical microscope (Olympus 
IX70-S8F2) equipped with a microinbucator (HCMIS ALA Science) to 
hold the temperature at 37°C. A commercial stand-alone AFM (Bio-
scope, Veeco) adapted to the optical microscope and provided with 
a low-spring constant (0.03 nN/nm) AFM cantilever (Veeco) was used 
to assess the Young’s modulus (E) of single cells, following a protocol 
described in detail elsewhere (Alcaraz et al., 2003, 2011). The spring 
constant of the cantilever was calibrated using the thermal fluctua-
tions method (Roca-Cusachs et al., 2008). In brief, three standard 
force versus displacement curves (F vs. z) were recorded on the peri-
nuclear region of each cell at moderate loading force (∼1 nN) and 
low speed (∼5 μm/s). The E of a single cell was computed by fitting 
a suitable contact elastic model to each F-versus-z curve and averag-
ing it over the three recordings. The final E for a cell population in 
each experimental condition was calculated from at least nine mea-
surements for each independent experiment (n ≥ 2).
Statistical analysis
Paired comparisons of data obtained from fibroblasts from the 
same patients were carried out using paired Student’s t test. Com-
parisons between each different cell types and IPF fibroblasts, be-
tween selected EMT models (A549, H1975) and control fibroblasts, 
or between FAK+/+ and FAK–/– fibroblasts were assessed by un-
paired Student’s t test. Statistical analyses were performed with 
either SigmaStat (Systat Software) or Graphpad Prism (Graphpad). 
Statistical significance was assumed at p < 0.05. Unless otherwise 
stated, data are given as mean ± SE for all independent experi-
ments (n ≥ 2).
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